BioVersys announces expansion of strategic collaboration with GSK
BioVersys AG announced the expansion of its strategic collaboration with GSK plc to accelerate the clinical development of alpibectir (BVL-GSK098) for the treatment of TB.
Alpibectir, a small molecule acting through a novel mode of action, was developed in a successful public-private collaboration with GSK, Pasteur Institute Lille and the University of Lille and is currently being evaluated in combination with ethionamide in a Phase 2a proof-of-concept study in pulmonary TB patients in South Africa. The compound represents a totally new concept of overcoming resistance and significantly potentiating the activity of an existing antibiotic, ethionamide.
Access the full press release here.
Source: BioVersys AG
